EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma

Yizhou Huang, Maohui Chen, Zhenyuan Yang, Bingqiang Cai, Yongcong Zhang, Shuliang Zhang, Taidui Zeng, Jun Yu, Chun Chen, Bin Zheng iD

The Oncologist · 06.06.2026 · 31 (7)

DOI: 10.1093/oncolo/oyag234 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 13.06.2026. Verfasst von Yizhou Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Research Center for Thoracic Tumors of Fujian Province, Fujian Province's special financial funds, Joint Funds for the Innovation of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lymphovascular (LVI) and perineural invasion (PNI) are adverse pathological features in esophageal squamous cell carcinoma (ESCC). We evaluated the prognostic significance of combined LVI/PNI (LNI) after neoadjuvant chemoimmunotherapy (nCIT) and the potential benefit of adjuvant therapy.

Methods

We retrospectively analyzed 473 ESCC patients undergoing nCIT followed by curative resection. LNI status was assessed in resected specimens. Survival outcomes were compared between LNI-positive and -negative patients using propensity score matching and multivariable Cox models. External validation was performed using an independent patient-level dataset.

Results

LNI was present in 21% of patients. LNI-positive patients had worse 3-year overall survival (OS) (49.8% vs 76.4%) and disease-free survival (DFS) (41.7% vs 69.3%), which remained significant after matching. LNI independently predicted inferior OS (hazard ratio [HR] 1.52, P = .022) and DFS (HR 1.40, P = .045). Recurrence occurred more frequently in LNI-positive patients (39.4% vs 19.8%, P < .001), predominantly locoregional. Among LNI-positive patients, adjuvant therapy improved 3-year OS (56.8% vs 32.4%) and DFS (49.7% vs 20.7%; adjusted HR 0.43, P = .002). External validation confirmed these findings, with independent prognostic impact of LNI and benefit from adjuvant therapy.

Conclusions

LNI after nCIT is an independent adverse prognostic factor in ESCC. Patients with these high-risk pathological features have markedly worse outcomes but appear to derive significant benefit from adjuvant therapy, supporting its incorporation into postoperative management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsHumansFemaleMaleMiddle AgedPrognosisNeoplasm InvasivenessAgedRetrospective StudiesChemotherapy, AdjuvantLymphatic MetastasisDisease-Free SurvivalImmunotherapy

Stichwörter der Autor:innen

adjuvant therapyesophageal squamous cell carcinomalymphovascular invasionneoadjuvant chemoimmunotherapyperineural invasion

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
  • Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University, Fuzhou, 350001, China.
  • National Key Clinical Specialty of Thoracic Surgery, Fuzhou, 350001, China.
  • Clinical Research Center, Thoracic Tumors of Fujian Province, Fuzhou, 350001, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, China.
  • Department of Thoracic Surgery, Quanzhou First Hospital, Fujian, 362000, China.

ORCID-Profile: Bin Zheng

Förderung

  • Clinical Research Center for Thoracic Tumors of Fujian Province
  • Fujian Province's special financial funds
  • Joint Funds for the Innovation of Science and Technology
  • Fujian Province’s special financial funds

Zitieren

APA

Huang, Y., Chen, M., Yang, Z., Cai, B., Zhang, Y., Zhang, S., Zeng, T., Yu, J., Chen, C., & Zheng, B. (2026). Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag234

Vancouver

Huang Y, Chen M, Yang Z, Cai B, Zhang Y, Zhang S, et al. Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag234

BibTeX
@article{Huang2026,
  author = {Huang, Yizhou and Chen, Maohui and Yang, Zhenyuan and Cai, Bingqiang and Zhang, Yongcong and Zhang, Shuliang and Zeng, Taidui and Yu, Jun and Chen, Chun and Zheng, Bin},
  title = {Lymphovascular and perineural invasion guides adjuvant therapy after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {7},
  doi = {10.1093/oncolo/oyag234}
}
Kostenlos starten →